MDM2 and acute myeloid leukemia: Although most of the studies are still in Phase I/II, MDM2 inhibitor RG7388 (idasanutlin) is now undergoing Phase III investigation for relapsed or refractory AML in combination with cytarabine, a DNA synthesis inhibitor.